API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The collaboration aims to focus on the ongoing clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, reversible, and highly selective P2Y12 inhibitor. It is being evaluated for the patients with Acute Myocardial Infarction.
Lead Product(s): Selatogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-246475
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: Undisclosed Upfront Cash: $350.0 million
Deal Type: Collaboration March 18, 2024
Details:
The collaboration aims to focus on the ongoing clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, reversible, and highly selective P2Y12 inhibitor. It is being evaluated for the patients with Acute Myocardial Infarction.
Lead Product(s): Selatogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-246475
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 27, 2024